MedTrace Logo

Biomarkers of CASH

NCT04467489 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1040

Last updated 2025-08-11

No results posted yet for this study

Summary

The project aims to develop prognostic and diagnostic blood tests for symptomatic brain hemorrhage in patients diagnosed with cavernous angiomas, a critical clinical challenge in a disease affecting more than a million Americans. We further examine whether blood biomarkers can replace or enhance the accuracy of advanced imaging in association with lesional bleeding. The project tests a novel integrational approach of biomarker development in a mechanistically defined cerebrovascular disease, with a clinically relevant context of use.

Conditions

  • Cerebral Cavernous Malformation
  • Cavernous Angioma
  • Hemorrhagic Microangiopathy

Interventions

OTHER

observational

There is no intervention for any group in this observational study.

Sponsors & Collaborators

  • Mayo Clinic

    collaborator OTHER

  • University of California, San Francisco

    collaborator OTHER

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Barrow Neurological Institute

    collaborator OTHER

  • University of Chicago

    lead OTHER

Principal Investigators

  • Issam Awad, MD · University of Chicago

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-22
Primary Completion
2025-04-30
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04467489 on ClinicalTrials.gov